Back

Critical appraisal on anti-inflammatory drugs

16 November 2025 (08:45 - 09:00)
Organised by: Logo
Seminar Presentation Part of: Residual Risk after ACS/PCI: It’s not just a matter of LDL Acute Coronary Syndromes, Other Open Access ESC Heart & Stroke 2025 and EuroThrombosis 2025 Council on Stroke

3 More presentations in this session

Presentation thumbnail
Inflammation: from hsCRP to IL1, through IL6
Slides
Presentation thumbnail
The additive role of Lp(a) on top of LDL lowering
Slides
Presentation thumbnail
Hypertriglyceridemia: combining diet, exercise training and drugs

Access the full session

Session thumbnail
Residual Risk after ACS/PCI: It’s not just a matter of LDL

The Event

Event poster

ESC Heart & Stroke 2025 and EuroThrombosis 2025

16 November 2025 08:45 CET
You may be interested in
thumbnail
Congress Session
Great Debate: anti-inflammatory therapy should be a part of atherosclerotic cardiac disease treatment
1 September 2025
thumbnail
Congress Presentation
1 September 2019
thumbnail
Congress Presentation
Is there value in prescribing colchicine in coronary artery disease for secondary prevention: a meta-analysis of over 5,000 patients
28 August 2020
thumbnail
Congress Presentation
2 September 2019

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources